[go: up one dir, main page]

WO2010014622A3 - In vitro model for modulating the blood brain barrier and methods of screening - Google Patents

In vitro model for modulating the blood brain barrier and methods of screening Download PDF

Info

Publication number
WO2010014622A3
WO2010014622A3 PCT/US2009/051978 US2009051978W WO2010014622A3 WO 2010014622 A3 WO2010014622 A3 WO 2010014622A3 US 2009051978 W US2009051978 W US 2009051978W WO 2010014622 A3 WO2010014622 A3 WO 2010014622A3
Authority
WO
WIPO (PCT)
Prior art keywords
brain barrier
methods
screening
blood brain
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/051978
Other languages
French (fr)
Other versions
WO2010014622A2 (en
Inventor
Elisabetta Dejana
Stefan Liebner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FONDAZIONE ISTITUTO FIRC DI ONCOLOGICA MOLECOLARE (IFOM)
Original Assignee
FONDAZIONE ISTITUTO FIRC DI ONCOLOGICA MOLECOLARE (IFOM)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FONDAZIONE ISTITUTO FIRC DI ONCOLOGICA MOLECOLARE (IFOM) filed Critical FONDAZIONE ISTITUTO FIRC DI ONCOLOGICA MOLECOLARE (IFOM)
Publication of WO2010014622A2 publication Critical patent/WO2010014622A2/en
Publication of WO2010014622A3 publication Critical patent/WO2010014622A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Instructional Devices (AREA)

Abstract

An in vitro blood brain barrier (BBB) model is provided as well as in vitro methods for screening molecules for the ability to pass through the BBB or the ability to tighten the endothelial cell junctions in the BBB.
PCT/US2009/051978 2008-07-28 2009-07-28 In vitro model for modulating the blood brain barrier and methods of screening Ceased WO2010014622A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8422508P 2008-07-28 2008-07-28
US61/084,225 2008-07-28
US8449208P 2008-07-29 2008-07-29
US61/084,492 2008-07-29
US19311608P 2008-10-29 2008-10-29
US61/193,116 2008-10-29

Publications (2)

Publication Number Publication Date
WO2010014622A2 WO2010014622A2 (en) 2010-02-04
WO2010014622A3 true WO2010014622A3 (en) 2010-05-06

Family

ID=41610935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/051978 Ceased WO2010014622A2 (en) 2008-07-28 2009-07-28 In vitro model for modulating the blood brain barrier and methods of screening

Country Status (1)

Country Link
WO (1) WO2010014622A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431231B (en) 2016-01-29 2021-09-10 豪夫迈·罗氏有限公司 Electrochemiluminescence methods and devices for detecting analytes in liquid samples
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
PT3583120T (en) 2017-02-17 2022-12-15 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
CN114107386B (en) * 2021-11-29 2024-02-02 中国人民解放军军事科学院军事医学研究院 A method of preparing a mouse model with blood-brain barrier deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (en) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6403325B1 (en) * 1997-06-30 2002-06-11 The Brigham And Women's Hospital, Inc. Methods and compounds for treating alzheimer's disease
WO2005063966A2 (en) * 2003-12-23 2005-07-14 Axaron Bioscience Ag Method for in vitro differentiation of neuronal stem cells or cells derived from neuronal stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403325B1 (en) * 1997-06-30 2002-06-11 The Brigham And Women's Hospital, Inc. Methods and compounds for treating alzheimer's disease
WO2001049709A1 (en) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
WO2005063966A2 (en) * 2003-12-23 2005-07-14 Axaron Bioscience Ag Method for in vitro differentiation of neuronal stem cells or cells derived from neuronal stem cells

Also Published As

Publication number Publication date
WO2010014622A2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2010002540A3 (en) Activation and monitoring of cellular transmembrane potentials
EP2260297A4 (en) EX VIVO MULTIDIMENSIONAL SYSTEM FOR THE SEPARATION AND ISOLATION OF CELLS, VESICLES, NANOPARTICLES AND BIOMARKERS
WO2008148105A8 (en) Endometrial stem cells and methods of making and using same
EP2727998A3 (en) Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells
AU325506S (en) Headphones
WO2009114601A3 (en) Preparation of lenalidomide
ZA201104035B (en) Clear to circular polarizing photochromic devices and methods of making the same
BRPI0810744A2 (en) ABSORBENT OXYGEN MOLECULES, OBJECTS CONTAINING THEM, AND METHODS OF USE
AU325844S (en) Filter package
WO2010019625A3 (en) Biocomposites and methods of making the same
WO2011011366A3 (en) Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP4509163A3 (en) Graft anchor devices, systems, and methods
WO2010062911A3 (en) Compositions and methods of functionally enhanced in vitro cell culture system
EP2352467A4 (en) Fluid collection system and methods of using same
WO2007097993A3 (en) Media conditioned by human embryonic stem cells or other progenitor cells and uses therefor
WO2011024172A3 (en) Liposomal compositions and uses of same
WO2012076985A8 (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
WO2011066288A3 (en) Systems and methods for enhancing growth of carbon-based nanostructures
WO2011119986A3 (en) Methods for culturing and analyzing cells
GEP20135800B (en) Method of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives preparation
WO2007100412A3 (en) Methods and compositions related to the modulation of riboswitches
WO2010014622A3 (en) In vitro model for modulating the blood brain barrier and methods of screening
WO2012053823A3 (en) Fusion protein having factor ix activity
WO2008111430A1 (en) METHOD FOR PRODUCING γδT CELL POPULATION
WO2010007441A3 (en) Phosphopeptides and use of the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803490

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09803490

Country of ref document: EP

Kind code of ref document: A2